CLRB (STOCKS)
Cellectar Biosciences INC NEW
$2.740000
-0.020000 (-0.72%)
Prev close: $2.760000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- James V. Caruso
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $11.45M
- Employees
- 11
- P/E (TTM)
- -0.26
- P/B (TTM)
- 1.46
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.29 | $-2.34 | +1.0492 | +44.85% |
|
Sep 2025 (Q3)
|
$-1.41 | $-2.58 | +1.1680 | +45.31% |
|
Jun 2025 (Q2)
|
$-3.39 | $-3.98 | +0.5880 | +14.78% |
|
Mar 2025 (Q1)
|
$-4.20 | $-5.00 | +0.7979 | +15.96% |
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $22.98M |
| Nonoperating Income/Loss | $1.19M |
| Research and Development | $11.50M |
| Operating Income/Loss | -$22.98M |
| Income/Loss From Continuing Operations After Tax | -$14.94M |
| Income/Loss From Continuing Operations Before Tax | -$21.79M |
| Income Tax Expense/Benefit | -$6.85M |
| Income Tax Expense/Benefit, Deferred | -$6.85M |
| Net Income/Loss | -$21.79M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$21.79M |
| Net Income/Loss Available To Common Stockholders, Basic | -$21.79M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$8.35 |
| Diluted Earnings Per Share | -$8.35 |
| Basic Average Shares | 2,608,317 |
| Diluted Average Shares | 2,608,317 |
| Assets | $14.98M |
| Current Assets | $14.04M |
| Noncurrent Assets | $939.86K |
| Fixed Assets | $549.41K |
| Other Non-current Assets | $390.45K |
| Liabilities | $5.06M |
| Current Liabilities | $4.75M |
| Accounts Payable | $1.44M |
| Other Current Liabilities | $3.31M |
| Noncurrent Liabilities | $309.40K |
| Equity | $8.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $8.54M |
| Liabilities And Equity | $14.98M |
| Net Cash Flow From Operating Activities | -$23.12M |
| Net Cash Flow From Operating Activities, Continuing | -$23.12M |
| Net Cash Flow From Investing Activities | -$5.88K |
| Net Cash Flow From Investing Activities, Continuing | -$5.88K |
| Net Cash Flow From Financing Activities | $13.03M |
| Net Cash Flow From Financing Activities, Continuing | $13.03M |
| Net Cash Flow | -$10.09M |
| Net Cash Flow, Continuing | -$10.09M |
| Comprehensive Income/Loss | -$21.79M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$21.79M |
| Other Comprehensive Income/Loss | $0.00 |